Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study.

Trial Profile

Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2013

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Biliary cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms XelOx-P07
  • Most Recent Events

    • 08 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top